Literature DB >> 7074754

Myocardial hydroxyproline reduced by early administration of methylprednisolone or ibuprofen to rabbits with radiation-induced heart disease.

W C Reeves, D Cunningham, E J Schwiter, A Abt, S Skarlatos, M A Wood, L Whitesell.   

Abstract

The ability of methylprednisolone (MP) and ibuprofen (IB) to reduce the severity of the late state of radiation-induced heart disease was assessed in 57 New Zealand white rabbits. Before and shortly after cardiac irradiation, 15 rabbits received i.v. MP, 30 mg/kg twice daily for 3 days, and 15 others received IB, 12.5 mg/kg twice daily for 2 days. No drug was administered to 14 irradiated rabbits, and neither irradiation nor drugs were administered to 13 rabbits that served as controls, All 15 rabbits treated with MP and 13 of the 15 treated with IB lived for 100 days. Only seven of the untreated, irradiated rabbits lived that long. Longevity of each treated group of rabbits was better (p less than 0.01 and 0.05) than that of the untreated, irradiated rabbits. Surviving rabbits were killed 100 days after irradiation. Pericarditis (p less than 0.05) and pericardial effusion (p less than 0.01) were less frequent in the treated, irradiated groups than in the untreated, irradiated rabbits. At least some rabbits in each irradiated group had microscopic evidence of myocardial fibrosis. The fibrosis was quantitated by determination of myocardial hydroxyproline concentrations (MHP). MHP concentration in the untreated, irradiated rabbits was greater than in those treated with MP (p less than 0.05) or IB (p less than 0.01) and in the untreated, unirradiated rabbits (p less than 0.01). Early administration of MP or IB retarded the development of myocardial fibrosis, pericarditis and pericardial effusion, and improved survival in this experimental model of radiation-induced heart disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074754     DOI: 10.1161/01.cir.65.5.924

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Treatment with Corticosteroid for Pericardial Effusion in a Patient with Advanced Synchronous Esophageal and Gastric Cancers following Chemoradiotherapy.

Authors:  Satoshi Osawa; Takanori Yamada; Takeji Saitoh; Takashi Kosugi; Tomohiro Terai; Yasuhiro Takayanagi; Yasushi Hamaya; Ken Sugimoto; Mutsuhiro Ikuma
Journal:  Case Rep Gastroenterol       Date:  2010-07-24

Review 2.  Ibuprofen in acute-care therapy.

Authors:  W B Rockwell; H P Ehrlich
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

Review 3.  Expanding the therapeutic index of radiation therapy by normal tissue protection.

Authors:  Pierre Montay-Gruel; Lydia Meziani; Chakradhar Yakkala; Marie-Catherine Vozenin
Journal:  Br J Radiol       Date:  2018-07-02       Impact factor: 3.039

Review 4.  Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems.

Authors:  Vijay K Singh; Thomas M Seed
Journal:  Expert Opin Pharmacother       Date:  2020-01-11       Impact factor: 3.889

Review 5.  Radiation-related heart disease: current knowledge and future prospects.

Authors:  Sarah C Darby; David J Cutter; Marjan Boerma; Louis S Constine; Luis F Fajardo; Kazunori Kodama; Kiyohiko Mabuchi; Lawrence B Marks; Fred A Mettler; Lori J Pierce; Klaus R Trott; Edward T H Yeh; Roy E Shore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 6.  Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside.

Authors:  Zsuzsanna Kahán; Tamás Csont; Márta Sárközy; Zoltán Varga; Renáta Gáspár; Gergő Szűcs; Mónika G Kovács; Zsuzsanna Z A Kovács; László Dux
Journal:  Clin Res Cardiol       Date:  2021-02-16       Impact factor: 5.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.